Skip to main content

Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Publication ,  Conference
Feng, A; Choi, T; Wu, J; Wang, X; Bellavia, T; Schrum, D; Eberwein, E; Cheng, S; Huggins, J; Tam, P; Kirby, S; Gasparetto, C; Costa Chase, C ...
Published in: Blood
November 5, 2024

Duke Scholars

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 5, 2024

Volume

144

Issue

Supplement 1

Start / End Page

2001 / 2001

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Feng, A., Choi, T., Wu, J., Wang, X., Bellavia, T., Schrum, D., … Kang, Y. (2024). Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma. In Blood (Vol. 144, pp. 2001–2001). American Society of Hematology. https://doi.org/10.1182/blood-2024-208621
Feng, Amber, Taewoong Choi, Jian Wu, Xiaobei Wang, Tanya Bellavia, Daniel Schrum, Erin Eberwein, et al. “Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma.” In Blood, 144:2001–2001. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-208621.
Feng A, Choi T, Wu J, Wang X, Bellavia T, Schrum D, et al. Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma. In: Blood. American Society of Hematology; 2024. p. 2001–2001.
Feng, Amber, et al. “Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 2001–2001. Crossref, doi:10.1182/blood-2024-208621.
Feng A, Choi T, Wu J, Wang X, Bellavia T, Schrum D, Eberwein E, Cheng S, Huggins J, Tam P, Kirby S, Gasparetto C, Costa Chase C, Long GD, Rowe-Nichols K, Kang Y. Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma. Blood. American Society of Hematology; 2024. p. 2001–2001.

Published In

Blood

DOI

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 5, 2024

Volume

144

Issue

Supplement 1

Start / End Page

2001 / 2001

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology